University of Adelaide

SUPLEXA Personalized Immunotherapy Shows Promise in Advanced Cancer Trial

7 months ago

• SUPLEXA, a personalized immunotherapy, demonstrated clinical benefits in patients with advanced cancers, particularly colorectal and renal cell carcinoma. • The first-in-human trial in Australia showed a strong safety profile for SUPLEXA, with no treatment-related serious adverse events reported. • Alloplex Biotherapeutics plans to initiate Phase 2 clinical trials combining SUPLEXA with immune checkpoint inhibitors for colorectal cancer in early 2025. • SUPLEXA involves ex vivo training of patient's immune cells to enhance their cancer-fighting abilities before reinfusion.

Alloplex's SUPLEXA Shows Promise in Advanced Cancer Patients via Immune Cell Retraining

7 months ago

• SUPLEXA, a personalized cancer treatment from Alloplex Biotherapeutics, retrains a patient's immune cells to fight advanced-stage cancer, showing potential in initial trials. • The first-in-human trial in Australia demonstrated a strong safety profile with no treatment-related serious adverse events across various advanced cancer types. • Notable clinical benefits were observed in colorectal cancer patients, including complete and partial responses, and in renal cell carcinoma patients, with partial responses and stable disease. • Encouraged by the FDA, Alloplex plans to initiate Phase 2 clinical trials in early 2025, combining SUPLEXA with immune checkpoint inhibitors for colorectal cancer.

Alloplex Biotherapeutics' SUPLEXA Shows Promise in Advanced Cancer Trial

7 months ago

• SUPLEXA, a personalized immunotherapy, demonstrated clinical benefits in advanced cancer patients by retraining their own immune cells to fight cancer. • The first-in-human trial showed significant responses in colorectal cancer (CRC) and renal cell carcinoma (RCC) patients, with a strong safety profile. • Alloplex Biotherapeutics plans to initiate Phase 2 clinical trials combining SUPLEXA with immune checkpoint inhibitors (ICIs) in CRC patients in early 2025. • The treatment involves a single blood draw, ex vivo immune cell training, and subsequent infusion, improving both cancer cell destruction and overall immune health.

Abbott Forges Partnerships and Advances Cardiac Rhythm Technologies

7 months ago

• Abbott partners with the Big Ten Conference for the 'We Give Blood Drive' to combat national blood shortages, incentivizing donations through a competition with a $1 million prize. • The VOLT-AF IDE study, evaluating Abbott's Volt PFA system for atrial fibrillation, has completed enrollment ahead of schedule, marking progress in pulsed field ablation technology. • Abbott's Lingo, a real-time glucose monitoring system designed for health and wellness, is now available in the U.S. without a prescription, offering insights into metabolic responses.

Abbott Advances Pulsed Field Ablation with Study Milestones and New Cardiac Mapping Tech

7 months ago

• Abbott completed enrollment in the VOLT-AF IDE study for its Volt PFA system ahead of schedule, marking progress in atrial fibrillation treatment. • The FOCALFLEX trial has been initiated to evaluate Abbott's TactiFlex Duo Ablation Catheter for paroxysmal atrial fibrillation using PFA and RF energy. • The FDA cleared Abbott's Advisor HD Grid X Mapping Catheter, enhancing cardiac mapping for PFA and RF ablation procedures, improving visualization. • These advancements underscore Abbott's commitment to refining PFA technology, addressing limitations of earlier systems, and improving outcomes for AFib patients.

PERSYST Study Uses Skin Samples to Resolve Uncertain Genetic Variants

8 months ago

• The PERSYST study, led by the University of Adelaide, is resolving variants of uncertain significance (VUS) using skin samples to extract RNA from disease-causing genes. • Innovative techniques like transactivation and transdifferentiation are used to activate silent genes in skin fibroblasts, enabling RNA sequencing and variant classification. • This approach aims to provide definitive diagnoses for patients with rare genetic diseases, opening access to clinical trials and precision therapies. • The study has successfully activated over 230 silent genes, offering new hope to individuals previously facing diagnostic uncertainty and limited treatment options.

Exosome Therapeutics and Diagnostics Pipeline Shows Promising Growth

8 months ago

• The exosome market is experiencing rapid growth, driven by advancements in liquid biopsy, precision medicine, and regenerative medicine. • Over 70 companies are developing 75+ exosome-based therapies, with several candidates in various clinical trial phases. • Exosome-based diagnostics are gaining traction, with two products already receiving Fast Track approval from the U.S. FDA. • The first exosome therapeutics are anticipated by 2029, offering advantages like targeted delivery and reduced side effects.

Novel Antibody-like Molecule Shows Promise for Broad-Spectrum Malaria Therapy

9 months ago

• Researchers have discovered WD34, a novel antibody-like molecule, that inhibits malaria parasite infection at various disease stages. • WD34 binds to the AMA1 protein, common across malaria species, blocking the mechanism parasites use to enter liver and red blood cells. • Pre-clinical trials suggest WD34 could protect against multiple malaria parasite species, offering a potential broad-spectrum therapeutic option. • The discovery opens new avenues for developing a universal malaria vaccine, addressing drug resistance and treatment failures.